Implementation of a low titer group O whole blood program for a law enforcement tactical team

Fisher, Andrew D; Dunn, John N.; Pickett, Jason; Garza, Justine; Miles, Edward F.; Diep, Vivian K.; Escott, Mark E A

doi:10.1111/trf.15625

Cited by 9 publications

(10 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there are no published studies looking at drone-based delivery of blood to a prehospital scene for use by trained personnel and further research in this area is needed. 83 , 84 , 85 , 86 , 87 , 88…”

Section: Drone-based Delivery Of Other Emergency Suppliesmentioning

confidence: 99%

Current summary of the evidence in drone-based emergency medical services care

Roberts¹,

Ager²,

Leith³

et al. 2023

Resuscitation Plus

View full text Add to dashboard Cite

Section: Drone-based Delivery Of Other Emergency Suppliesmentioning

confidence: 99%

Current summary of the evidence in drone-based emergency medical services care

Roberts¹,

Ager²,

Leith³

et al. 2023

Resuscitation Plus

View full text Add to dashboard Cite

“…Based on hemovigilance data from many countries over decades, this is a safe procedure not increasing the risk of bacterial infections in the recipients 4,5 . Blood collected in a military walking blood bank is not LR 6 . When personnel, often with limited training, collect blood in a walking blood bank where hygiene procedures cannot be satisfactorily accomplished, there is a higher risk of bacterial contamination in the donated blood.…”

Section: Introductionmentioning

confidence: 99%

“…4,5 Blood collected in a military walking blood bank is not LR. 6 When personnel, often with limited training, collect blood in a walking blood bank where hygiene procedures cannot be satisfactorily accomplished, there is a higher risk of bacterial contamination in the donated blood. Reducing the risk of bacterial contamination is therefore of importance.…”

Section: Introductionmentioning

confidence: 99%

Effect of leukoreduction and temperature on risk of bacterial growth in CPDA‐1 whole blood: A study of Escherichia coli

et al. 2021

View full text Add to dashboard Cite

Background Collection of non‐leukoreduced citrate‐phosphate‐dextrose‐adenine (CPDA‐1) whole blood is performed in walking blood banks. Blood collected under field conditions may have increased risk of bacterial contamination. This study was conducted to examine the effects of WBC reduction and storage temperature on growth of Escherichia coli (ATCC® 25922™) in CPDA‐1 whole blood. Methods CPDA‐1 whole blood of 450 ml from 10 group O donors was inoculated with E. coli. Two hours after inoculation, the test bags were leukoreduced with a platelet‐sparing filter. The control bags remained unfiltered. Each whole blood bag was then split into three smaller bags for further storage at 2–6°C, 20–24°C, or 33–37°C. Bacterial growth was quantified immediately, 2 and 3 h after inoculation, on days 1, 3, 7, and 14 for all storage temperatures, and on days 21 and 35 for storage at 2–6°C. Results Whole blood was inoculated with a median of 19.5 (range 12.0–32.0) colony‐forming units per ml (CFU/ml) E. coli. After leukoreduction, a median of 3.3 CFU/ml (range 0.0–33.3) E. coli remained. In the control arm, the WBCs phagocytized E. coli within 24 h at 20–24°C and 33–37°C in 9 of 10 bags. During storage at 2–6°C, a slow self‐sterilization occurred over time with and without leukoreduction. Conclusions Storage at 20–24°C and 33–37°C for up to 24 h before leukoreduction reduces the risk of E. coli‐contamination in CPDA‐1 whole blood. Subsequent storage at 2–6°C will further reduce the growth of E. coli.

show abstract

“…The risk can be minimized with plasma products containing low‐titer antibodies 19 . Moreover, the use of O whole blood with low‐titer antibodies for emergency/massive transfusion has been described 20‐22 . The use of group A plasma is suggested as an acceptable alternative to AB plasma 23,24 .…”

Section: Discussionmentioning

confidence: 99%

Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma

Yang

Ryu

Kim

et al. 2021

J of Clinical Apheresis

View full text Add to dashboard Cite

Background Criteria for selection of FFP blood type has not been clearly established and use of group AB plasma is preferred by numerous transplantation protocols. Aims This study assesses the safety and efficacy of alternative group A or B plasma in ABO incompatible solid organ transplantation. Materials & Methods Alternative use of group A or B plasma (incompatible plasma) was inevitable during the shortage of group AB plasma. Experience from select number of patients during the period of extreme group AB plasma shortage is described. Results The result of alternative use of group A or B plasma was within expectation, showing effective reduction of isoagglutinin titers for pre‐operative desensitization and efficacy for treatment of post‐operative patients. No immediate hemolytic transfusion reaction was reported. Discussion While validation in a larger cohort of patients is necessary, our limited experience have shown satisfactory clinical outcomes without adverse events. Conclusions Use of incompatible group A or B plasma is a viable option when group AB plasma is limited.

show abstract

Implementation of a low titer group O whole blood program for a law enforcement tactical team

Cited by 9 publications

References 55 publications

Current summary of the evidence in drone-based emergency medical services care

Current summary of the evidence in drone-based emergency medical services care

Effect of leukoreduction and temperature on risk of bacterial growth in CPDA‐1 whole blood: A study of Escherichia coli

Evaluation of safety of using incompatible plasma for therapeutic plasma exchange during shortage of AB plasma

Contact Info

Product

Resources

About